1
/
of
1
Elabscience
SKU:PKSM040597
Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)(Active)
Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)(Active)
Regular price
$805.00 USD
Regular price
Sale price
$805.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Mouse Vascular Endothelial Growth Factor Receptor 3/Fms-like Tyrosine Kinase 4 Protein (Fc Tag) in its active form. This meticulously engineered protein offers a cutting-edge solution for researchers and scientists seeking to explore the intricate mechanisms of angiogenesis and lymphangiogenesis.
The Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)(Active) is a fusion protein that combines the extracellular domain of the mouse VEGFR3/FLT4 receptor with the Fc region of human IgG1. This fusion construct ensures enhanced stability, solubility, and bioactivity, enabling reliable and reproducible experimental results.
This product exhibits remarkable specificity and affinity towards its ligands, including VEGF-C and VEGF-D, thereby facilitating the investigation of their intricate signaling pathways. The active form of this recombinant protein guarantees optimal functionality, enabling accurate evaluation of downstream cellular responses and signaling cascades.
The Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)(Active) is meticulously produced using advanced recombinant DNA technology, ensuring high purity and batch-to-batch consistency. Rigorous quality control measures are implemented throughout the manufacturing process to guarantee the utmost reliability and performance of this protein.
This protein is supplied in lyophilized form, preserving its stability and activity during storage and transportation. Upon reconstitution, it can be readily utilized in a wide range of applications, including but not limited to ligand binding assays, receptor-ligand interaction studies, and functional analysis of VEGFR3/FLT4-mediated signaling pathways.
In summary, the Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)(Active) represents a state-of-the-art tool for researchers and scientists aiming to unravel the complexities of angiogenesis and lymphangiogenesis. Its exceptional purity, stability, and bioactivity make it an indispensable asset in various experimental settings, ultimately contributing to advancements in the field of vascular biology and therapeutic development.
The Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)(Active) is a fusion protein that combines the extracellular domain of the mouse VEGFR3/FLT4 receptor with the Fc region of human IgG1. This fusion construct ensures enhanced stability, solubility, and bioactivity, enabling reliable and reproducible experimental results.
This product exhibits remarkable specificity and affinity towards its ligands, including VEGF-C and VEGF-D, thereby facilitating the investigation of their intricate signaling pathways. The active form of this recombinant protein guarantees optimal functionality, enabling accurate evaluation of downstream cellular responses and signaling cascades.
The Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)(Active) is meticulously produced using advanced recombinant DNA technology, ensuring high purity and batch-to-batch consistency. Rigorous quality control measures are implemented throughout the manufacturing process to guarantee the utmost reliability and performance of this protein.
This protein is supplied in lyophilized form, preserving its stability and activity during storage and transportation. Upon reconstitution, it can be readily utilized in a wide range of applications, including but not limited to ligand binding assays, receptor-ligand interaction studies, and functional analysis of VEGFR3/FLT4-mediated signaling pathways.
In summary, the Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)(Active) represents a state-of-the-art tool for researchers and scientists aiming to unravel the complexities of angiogenesis and lymphangiogenesis. Its exceptional purity, stability, and bioactivity make it an indispensable asset in various experimental settings, ultimately contributing to advancements in the field of vascular biology and therapeutic development.
Share
